Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

59.10GBp
23 Aug 2019
Change (% chg)

-1.58 (-2.60%)
Prev Close
60.68
Open
61.56
Day's High
61.56
Day's Low
58.64
Volume
1,674,688
Avg. Vol
5,278,735
52-wk High
278.10
52-wk Low
20.98

Select another date:

Wed, Jul 31 2019

Indivior posts 14% rise in quarterly profit

July 31 Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace, than the company's previous modelling had expected.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Indivior signs deal to sell schizophrenia drug in Canada

May 9 British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Indivior's Suboxone decline slower than feared as company bets on new opioid drug

Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.

Indivior's Suboxone decline slower than feared as company bets on new opioid drug

Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.

UPDATE 3-Indivior's Suboxone decline slower than feared as company bets on new opioid drug

* Stock closes up 5.2 percent (Adds graphics, CFO comment, details on DoJ investigation)

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

(This April 10 story refiles to fix scrambled syntax in paragraph five)

Select another date: